Investigación

CoViproteHCt

Imagen 3D coronavirus
Foto: Freepik user2109397
Duración
18/4/2020 - 31/12/2021
Coordinador
Technische Universität München
Financiadores
EIT Health

The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.

Funding

678.671 €

Nuestro equipo

Equipo ISGlobal

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

COVID-PREG

Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo